Market Overview

MTS Systems Initiated Overweight By JPMorgan

MTS Systems Initiated Overweight By JPMorgan

MTS Systems Corporation (NASDAQ: MTSC) shares have plummeted 30 percent year-to-date. JPMorgan’s Paul Coster initiated coverage of the company with an Overweight rating and a price target of $54. The analyst believes the company’s stock is currently undervalued, given the prospects of 2H and long-term margin expansion.

MTS Systems’ shares have recently been under pressure due to recent execution challenges and the debt burden associated with the PCB acquisition. Analyst Paul Coster said, however, that the company’s margins were poised to expand in 2H, while there could be an upward revision of the long-term growth and margin prospects.

Related Link: MTS Announces Upsized 1.65M Share Offering Of Common Stock @$42.00/Share

Margin Expansion In 2H

Coster expects the Test segment’s revenue and margin to reaccelerate in the back half of the year. He wrote, “Based on two years of strong bookings, record segment backlog, and the recent addition of resources necessary to execute, we expect custom projects to conclude in 2H, unleashing 5-10% y/y revenue growth and higher EBITDA margins.”

Upward revision Of LT Prospects

The successful integration of the PCB acquisition is likely to boost sensor growth and be margin accretive. While PCB should benefit from MTS Systems’ global reach and Test market cross-selling, MTS Systems would benefit from scale and synergies. “Combined with MTS, PCB should yield a significant increase in MTS’s EBITDA margin by FY18,” the analyst added.

Latest Ratings for MTSC

Feb 2017DowngradesOverweightNeutral
Aug 2016Initiates Coverage onMarket Perform
Jun 2016Initiates Coverage onOverweight

View More Analyst Ratings for MTSC
View the Latest Analyst Ratings

Posted-In: JPMorgan Paul CosterAnalyst Color Long Ideas Initiation Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (MTSC)

View Comments and Join the Discussion!

Capricor Therapeutics Provides Enrollment Update on HOPE Clinical Trial in Duchenne Muscular Dystrophy

LyondellBasell Downgraded By JP Morgan, Price Target Cut 20%